Canaccord Genuity Reaffirms Buy Rating on Momenta Pharmaceuticals (MNTA)
A number of other firms have also recently commented on MNTA. Analysts at Goldman Sachs (NYSE: GS) reiterated a “neutral” rating on shares of Momenta Pharmaceuticals in a research note to investors on Friday, February 10th. Analysts at Zacks downgraded shares of Momenta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, February 9th.
Shares of Momenta Pharmaceuticals traded down 0.36% during mid-day trading on Friday, hitting $13.81. Momenta Pharmaceuticals has a 52 week low of $10.15 and a 52 week high of $21.00. The company has a market cap of $693.8 million and a P/E ratio of 5.94.
Momenta Pharmaceuticals last announced its earnings results on Thursday, May 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.12. The company’s revenue for the quarter was down 69.1% on a year-over-year basis. On average, analysts predict that Momenta Pharmaceuticals will post $-0.25 earnings per share next quarter.
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.